← Markets

Avalyn Pharma Inc. Common Stock

AVLN · NASDAQ

Market open$28.31$0.010000 (+0.04%)

Chart data is refreshing.

Key statistics

Previous close$28.30
Open$28.30
Day high$28.31
Day low$28.31
52-week high$33.32
52-week low$24.15
Market cap1.26B
Volume441.00
Average volume519.64K
P/E ratio-1.30
Forward P/E—
EPS-21.83
Dividend yield0.00%

Market context

Why it moved

AVLN surged sharply higher after bullish technical analysis highlighted the stock breaking out from a massive multi-year consolidation base, with increased institutional and mutual fund participation signaling strong smart money interest in the aquaculture and seafood sector.

InstagramMarketbeatSubstackWeatherTrefis

What is happening

Recent company-specific developments and publisher coverage.

July 20, 2026Avalyn Pharma surged over 10% from its prior close of $25.68, touching a pre-market high of $29.27, buoyed by sustained analyst conviction — five research firms maintain a consensus 'Buy' rating with an average 12-month price target of $59, more than double current levels. The rally builds on last Friday's 5.3% gain and notable insider confidence, including a $5M purchase by Director Jill Carroll and a $10M acquisition by SR One Capital Management in May, even as the company posted a wider-than-expected quarterly loss of ($21.83) EPS vs. the ($16.38) consensus.

10.2025

July 17, 2026Avalyn Pharma surged over 10% on the session, significantly outperforming the broader healthcare sector (XLV closed lower), as Wall Street's bullish analyst coverage continues to draw investor attention. Multiple major firms — including Guggenheim, Jefferies, Evercore, and Morgan Stanley — initiated coverage in May with Buy/Outperform ratings and price targets ranging from $51 to $80, implying substantial upside from current levels against a consensus target of $59. The strong move comes amid a favorable backdrop for pharma, with UBS upgrading the healthcare sector as a key allocation focus and Q2 earnings season highlighting pharmaceutical strength.

10.2025

July 16, 2026Avalyn Pharma shares declined, underperforming the broader healthcare sector (XLV closed roughly flat) as the clinical-stage biopharma faces a binary data-driven narrative: its Phase 2b MIST trial of AP01 (inhaled pirfenidone) completed target enrollment in June, with topline 12-month results not expected until the second half of 2027. With no near-term catalysts on the horizon, thin trading volume—well below its average—and a mixed healthcare backdrop shaped by HCA's profit forecast cut and managed care headwinds, investors remain cautious on pre-revenue rare respiratory disease plays.

-3.1117

July 14, 2026Avalyn Pharma edged higher amid a mixed session for healthcare stocks, with the XLV sector ETF closing lower as the broader pharma space navigated a challenging backdrop. Investors are eyeing major upcoming Q2 earnings from Johnson & Johnson, UnitedHealth, and Abbott — which together represent over 20% of XLV — as the healthcare sector faces a projected 9% earnings decline largely tied to Gilead accounting effects. Meanwhile, macro crosscurrents including a softer-than-expected June CPI print, renewed US-Iran tensions driving oil higher, and a hawkish Fed posture continued to weigh on sector sentiment, while Morningstar flagged biopharma names as presenting solid Q3 opportunities.

1.5805

July 13, 2026Avalyn Pharma closed modestly lower as the broader healthcare sector faced headwinds from a risk-off session driven by renewed U.S.-Iran tensions, which sent oil prices surging and weighed on equities. The XLV healthcare ETF also edged lower amid sector-wide caution ahead of major Q2 earnings reports from J&J, UnitedHealth, and Abbott later this week, with healthcare sector earnings broadly forecast to decline 9% year-over-year. Goldman Sachs research highlighting strong biotech M&A momentum and biopharma innovation cycles offers a constructive backdrop for smaller pharma names like Avalyn.

-0.784

July 8, 2026Avalyn Pharma closed up roughly 1.83%, outperforming a broadly mixed market as healthcare emerged as one of the strongest sectors on the day, with 91% of S&P 500 healthcare stocks showing relative strength — their best collective performance in over 15 years. The XLV healthcare ETF also advanced, benefiting from a continued rotation out of tech amid renewed U.S.-Iran tensions in the Persian Gulf that rattled AI-linked chip stocks and lifted oil prices, reinforcing healthcare's appeal as a defensive play. Health Care was the second-best performing S&P 500 sector in June (+6.6%) and has posted back-to-back market-leading weekly performances heading into July.

1.8297

July 8, 2026Avalyn Pharma gained nearly 3% as healthcare emerged as a standout sector for a second consecutive week, with XLV trading near 52-week highs amid a broad rotation out of technology into defensive and healthcare names. The move came against a backdrop of softer macro data — a weak June jobs report showing only 57,000 new roles — and investor appetite for pharma resilience, even as broader healthcare sector earnings are projected to decline year-over-year in Q2.

2.7848

July 1, 2026Avalyn Pharma shares tumbled roughly 8% on elevated volume, pulling back sharply after closing at their session high the prior day. The decline comes days after the company was added to multiple Russell indexes — including the Russell 2000, Russell 2000 Value, and Russell 2000 Growth benchmarks — effective June 29, an event that often triggers buy-the-news selling once index-driven buying subsides. Analyst consensus still carries a price target of $59, implying significant upside, while the broader healthcare sector (XLV) closed essentially flat, suggesting the move was stock-specific rather than sector-driven.

-8.3536

MarketBeat · July 18, 2026Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Average Rating of "Buy" from AnalystsMarketBeat · July 17, 2026Avalyn Pharma (NASDAQ:AVLN) Shares Up 5.3% - Here's WhyThe Business Journals · April 9, 2026Boston biotech Avalyn Pharma files to go public after $100M funding roundBioPharma Dive · April 9, 2026Chasing a tough-to-treat lung disease, Avalyn plans an IPORenaissance Capital · April 8, 2026AVLN IPO News - Pulmonary fibrosis biotech Avalyn Pharma files for a $100 million IPOGlobeNewswire · March 23, 2026Avalyn Announces First Patient Dosed in AURA Phase 2

Peers

S&P 500SPX · $7,498.04+0.54%Alnylam Pharmaceuticals, Inc.ALNY · $266.79-0.25%Vertex Pharmaceuticals IncorporatedVRTX · $487.54+0.39%Regeneron Pharmaceuticals, Inc.REGN · $676.90+0.03%argenx SEARGX · $863.39+0.33%Twist Bioscience CorporationTWST · $93.85+2.87%CG Oncology Inc.CGON · $71.85+3.38%CRISPR Therapeutics AGCRSP · $47.75-0.06%United Therapeutics CorporationUTHR · $535.67+1.25%Bristol-Myers Squibb CompanyBMY · $60.86+0.20%Contineum Therapeutics, Inc.CTNM · $14.23+1.57%Eli Lilly and CompanyLLY · $1,179.52+0.03%